Treatment of type i gastric neuroendocrine tumors with somatostatin analogs

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 3, 2010, Pages 548-554

  Khuroo, Mohammad Sultan ^b   Khuroo, Mehnaaz Sultan ^a   Khuroo, Naira Sultan ^b  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b Dr Khuroo's Medical Clinic   (India)

Author keywords

Chromogranin; Enterochromaffin like cells; Gastrin; Neuroendocrine tumors; Octreotide; Somatostatin analogs

Indexed keywords

CHROMOGRANIN; GASTRIN; OCTREOTIDE;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; FEMALE; FOLLOW UP; GASTROSCOPY; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; STOMACH TUMOR; TREATMENT OUTCOME; TUMOR BIOPSY; TYPE I GASTRIC NEUROENDOCRINE TUMOR; ATROPHIC GASTRITIS; DRUG TOLERABILITY; ESOPHAGOGASTRODUODENOSCOPY; GASTRIN BLOOD LEVEL; HYPERGASTRINEMIA; TUMOR RECURRENCE;

EID: 77649204858     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06131.x     Document Type: Article

References (22)

1. Kulke MH, Mayor RJ. Carcinoid tumors. N. Engl. J. Med. 1999 340 : 858 868.
2. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997 79 : 813 829.
3. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am. J. Gastroenterol. 1995 90 : 338 352.
4. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993 104 : 994 1006.
5. Debelenko LV, Emmert-Buck MR, Zhuang Z et al. The multiple endocrine neoplasia type 1 gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 1997 113 : 773 781.
6. Eckhauser FE, Llyod RV, Thompson NW, Raper SE, Vinik AI. Antrectomy for multicentric, Argyrophill gastric carcinoids: a preliminary report. Surgery 1988 104 : 1046 1053.
7. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffin-like cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992 102 : 1409 1418.
8. Tomasetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of Type II gastric carcinoid tumors with somatostatin analogues. N. Engl. J. Med. 2000 343 : 551 554.
9. Caplin ME, Hodgson HJ, Dhillon AP et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am. J. Gastroenterol. 1998 93 : 1945 1948.
10. Grozinsky-Glasberg S, Kaltsas G, Gur C et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur. J. Endocrinol. 2008 159 : 475 482.
11. Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand. J. Gastroenterol. 2005 40 : 1269 1274.
12. Campana D, Nori F, Pezzilli R et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogues. Endocr. Relat. Cancer 2008 15 : 337 342.
13. Manfredi S, Pagenault M, De Lajarte-Thirouard AS, Bretagne JF. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur. J. Gastroenterol. Hepatol. 2007 19 : 1021 1025.
14. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J. Surg. Oncol. 2006 93 : 368 372.
15. Ferraro G, Annibale B, Marignani M et al. Effectiveness of Octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J. Clin. Endocrinol. Metab. 1996 81 : 677 683.
16. Lehy T, Roucayrol AM, Mignon M. Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. Microscopy Res. Technique. 2000 48 : 327 338.
17. Waldum HL, Sandvik AK, Idle JR. Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 1998 114 : 1113 1115.
18. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand. J. Gastroenterol. 2004 39 : 621 628.
19. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006 17 : 1733 1742.
20. Hosokawa O, Kaizaki Y, Hattori M et al. Long term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005 8 : 42 6.
21. Ahlam H, Kolby L, Lundell L et al. Clinical management of gastric carcinoid tumors. Digestion 1994 55 (Suppl. 3 77 85.
22. Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow-up of pernicious anemia patients. Gut 1993 34 : 28 32.